Stock Ratings / Health Care / ABSI / financials

OABI (38) NRC (65) ICLR (71) CRL (63) ⌘ Pro Terminal →

Absci Corporation (ABSI) Revenue-to-Profit Sankey Flow & SEC XBRL Financials

$12.10 +1.85% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $12.12

Absci Corporation (ABSI) carries a Roarable Rating of D (Sell) with 45/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (45/100 · D) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE D • SELL / AVOID Cap $2.08B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $12.12 (+0.14%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 6/20 (E) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (45/100 · D) historically underperformed SPY in 71% of rolling 90-day windows (-6.3% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERSELL / AVOID • D

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk D+

Each axis scored 0–20

12M PRICE TARGET CONE-5.9% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for ABSI)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (45/100 Composite)

🔍 WHY ABSI SCORES 45/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Whale & Options Positioning+14/20 pts (31% of score)

20D Institutional Volume Accumulation (±12.5% realized swing band)

▲ #2 Bullish Driver: Macro Regime Fit+12/20 pts (27% of score)

FRED Regime × Technicals: 96% of 52W Range • RSI-14 at 57.7 (BULLISH MOMENTUM)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade E$10.16-18.8% Next Q

Q2 (-2Q)

Grade D$8.25+11.3% Next Q

Q3 (-1Q)

Grade D$9.18+31.8% Next Q

Current

Grade D$12.10-6.3% Hist 90D α

Trajectory: E (37) → D (45)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a ABSI Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While ABSI currently carries a cautious 45/100 (D) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($9.51) and Max Pain ($12.71) forces dealer call-delta covering toward $13.44.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $ABSI• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “ABSI Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 45%NO 55%Trade / Inspect Odds →

VISUAL REVENUE-TO-PROFIT SANKEY WATERFALL • FY 2025 (10-K)

How ABSI Turns Every Dollar of Sales Into Real Bottom-Line Profit

Free Cash Flow:$0 (0% FCF Margin)

Multi-Year SEC EDGAR XBRL Revenue, Net Profit & Free Cash Flow Trajectory

■ Revenue■ Net Profit■ Free Cash Flow

FY23

Rev $5.7M

FY24

Rev $4.5M

FY25

Rev $4.00B

Fiscal Year	Revenue	Gross Margin	Op Margin	Net Profit	Free Cash Flow	ROIC %
FY 2025	$4.00B	52%	-3%	-$115.2M	-$94.0M	-45%
FY 2024	$4.5M	52%	-80%	-$103.1M	-$72.8M	-45%
FY 2023	$5.7M	52%	-80%	-$110.6M	-$64.6M	-35%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring ABSI)

✓Walkthrough of ABSI's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

ABSI // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +143.46%▲ ASCENDING CHANNEL

2026-10-30O $11.41H $12.10L $10.45C $12.10VOL 4.56M

RES: $12.94SUP: $8.38SMA50: $9.51SMA200: $6.49

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

ABSI Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 ABSI Butterfly Map → + Track ABSI →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on ABSI today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for ABSI. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for ABSI today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (ABSI)

Health Care Rank #472 of 1016 ⚔️ OABI vs ABSI Full Matrix →

1. Head-to-Head Health Care Peer Comparison (ABSI vs. OABI, NRC, ICLR, CRL)

Industry: Biotechnology: Commercial Physical & Biological Resarch (12 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Absci Corporation (ABSI) ranks #472 by composite RQD confidence (45/100, grade D) and #255 by equity capitalization ($2.08B). Within this direct 5-issuer industry benchmark cohort, NRC leads on earnings valuation at 44.8x trailing P/E, while NRC leads on capital efficiency and profitability with 21.0% ROIC and — gross margin. ICLR currently holds the highest overall quantitative score in the immediate peer group at 71/100 (B-) compared with ABSI at 45/100 (D).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
ABSI ACTIVE Absci Corporation	D	45/100	—	—	-35.0%	+1.85%	$2.08B	Benchmark Subject
OABI OmniAb Inc.	D-	38/100	—	—	-22.6%	-0.95%	$760.4M	/oabi-vs-absi →
NRC NRC Health	C	65/100	44.8x	—	21.0%	+0.09%	$519.6M	/nrc-vs-absi →
ICLR ICON plc	B-	71/100	71.9x	—	3.1%	+0.62%	$16.50B	/iclr-vs-absi →
CRL Charles River Laboratories International Inc.	C	63/100	—	—	0.4%	+0.57%	$17.95B	/crl-vs-absi →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001672688

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Absci Corporation (ABSI) reported GAAP revenue of $0 (-100.0% vs. FY2024 revenue of $4.5M , and -100.0% cumulative change since FY2023) , GAAP net income of -$115.2M, operating cash flow of -$92.9M, and free cash flow of -$94.0M (-29.2% YoY). On the balance sheet, ABSI closed FY2025 with $216.3M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$0	-$115.2M	-$92.9M	-$94.0M	$216.3M	—
FY2024 (FY)	2024-12-31	$4.5M	-$103.1M	-$72.4M	-$72.8M	$213.6M	—
FY2023 (FY)	2023-12-31	$5.7M	-$110.6M	-$64.6M	-$64.6M	—	—

3. ABSI Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is ABSI stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Absci Corporation (NASDAQ: ABSI) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 45/100 at a spot price of $12.10 (+1.85% 1D, market cap $2.08B). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 14/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 12/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, ABSI ranks #472 in composite RQD confidence.

How does ABSI compare to OABI and NRC in the Health Care sector?

Within the Health Care sector (Biotechnology: Commercial Physical & Biological Resarch), ABSI carries a Roarable D (45/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, OABI (OmniAb Inc.) holds a D- grade (38/100 RQD, P/E N/A, ROIC -22.6%, cap $760.4M) and NRC (NRC Health) posts a C grade (65/100 RQD, P/E 44.8x, ROIC 21.0%, cap $519.6M). Among the 5-stock peer group, NRC leads on earnings multiple (44.8x) while NRC leads on capital efficiency (21.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for ABSI?

Per ABSI's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001672688), Absci Corporation generated $0 in revenue (-100.0% YoY), -$115.2M in net income, and -$94.0M in free cash flow against $216.3M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is ABSI trading relative to its 50-day, 200-day, and 52-week technical levels?

ABSI last traded at $12.10 (+1.85% on volume of 4,337,446 shares), positioning the stock +27.23% above its 50-day simple moving average ($9.51) and +86.44% above its 200-day simple moving average ($6.49). Across its 52-week range of $2.24 to $12.55, ABSI sits at the 95.6% percentile with a 14-day RSI of 57.7 (BULLISH MOMENTUM) and an implied next-earnings move of ±12.5% ($10.59 to $13.61).

ABSI Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

How profitable is Absci Corporation (ABSI)?

In FY 2025 (10-K), ABSI converted $4.0B of revenue into a 52% gross margin, 0% operating margin, and $0 in free cash flow (0% FCF margin).

Direct Sub-Reports: ABSI RQD Cockpit ABSI 12M Forecast ABSI Earnings & Move ABSI Dividends & DRIP ABSI Insiders & 13F ABSI Whale Options ABSI Profit Sankey ABSI News & Why